Objectives: Antibiotic resistance among Escherichia coli is globally an increasing problem in public healthcare. Understanding the spread of plasmid-mediated ESBL genes is of great importance in elucidating their molecular epidemiology. However, differentiation of subtypes and alleles is frequently hampered by the lack of comprehensive diagnostic tools. We therefore developed a novel universal bla SHV , bla TEM and bla CTX-M subtyping assay based on PCR and Sanger sequencing that results in large amplicons of .700 bp, enabling differentiation of bla alleles as precisely as possible.
Introduction
The increasing resistance of potentially pathogenic bacteria to multiple conventional antibiotics is an urgent problem in global public health. ESBL-producing Escherichia coli are amongst the most prevalent Gram-negative MDR organisms. These bacteria are resistant to several clinically important b-lactam antibiotics, such as third-and fourth-generation cephalosporins, penicillins and aztreonam. 1 -3 Clinically relevant ESBLs are generally encoded by plasmid-mediated bla genes, and may thus be transmitted between different bacteria by horizontal gene transfer. A variety of different allelic variants, which can cause different phenotypes, is known for each gene. 4 Extended-and broad-spectrum variants of one bla gene may coexist in one bacterial genome, as well as different bla genes.
Three major clinically relevant b-lactamase genes are bla SHV , bla TEM and bla CTX-M . 2, 4 Although bla SHV and bla TEM comprise many allelic variants of extended-as well as broad-spectrum phenotype, all alleles are rather homogeneous in their amino acid sequence. In contrast, bla CTX-M alleles are heterogeneous and inherently express an ESBL phenotype. 5 They can be subdivided into five different subgroups around the enzymes CTX-M-1, -2, -8, -9 and -25, respectively. 5 -7 A better understanding of the molecular epidemiology of bla genes and their particular ESBL alleles is very important for the successful prevention of infections caused by MDR Gram-negative bacteria. A key element for successful surveillance is the improvement of detection and diagnostic methods based on nucleic acids. 8 Many non-phenotypic tests for the detection and subtyping of ESBL-relevant b-lactamases have already been proposed and established (reviewed by Lupo et al. 9 ). However, most assays are limited to screening for certain bla alleles or simply differentiate between the mentioned allele groups. To our knowledge, there is not yet a universal assay that allows the rapid and reliable identification of the exact b-lactamase alleles within a single experimental approach. Hence, in this study, we present a novel universal bla SHV , bla TEM and bla CTX-M subtyping assay based on PCR and Sanger sequencing, which can be easily implemented in clinical routine laboratories.
Materials and methods

Bacterial isolates
Ten ESBL-positive E. coli isolates with known allele types of the investigated bla SHV , bla TEM and bla CTX-M genes were obtained from the German National Reference Laboratory for MDR Gram-negative bacteria (NRL, RuhrUniversity Bochum, Germany). These were used as positive control strains for the establishment of the novel assay. At least one positive control strain was available for every examined primer/allele group, with the exception of the rare b-lactamase CTX-M-25: bla SHV-2 and -12 , bla TEM-52 , bla CTX-M-1 , -3 and -15 , bla CTX-M-9 and -14 , bla CTX-M-2 cluster and bla CTX-M-8 . The primers used for the amplification of bla CTX-M-25 were also used to amplify the related group bla CTX-M-8 , and thus the functionality of these primers was tested in the novel assay.
A large test set (n ¼ 101) of clinical (n ¼ 40; from two studies of the University Hospital of Mü nster, Germany) and livestock-associated (n¼61; from the German federal state Mecklenburg -Western Pomerania) ESBL-positive E. coli isolates with unknown genotypes, assumed to cover a wide range of bla alleles, was used to validate the novel assay (Table S1 , available as Supplementary data at JAC Online). Sixteen clinical ESBL-positive E. coli (study 1) were isolated from ICU patients from April 2009 to June 2010; the other 24 samples (study 2) were isolated from bloodstream infections in 2012 from normal and ICU patients. Fifty-six ESBL-positive E. coli isolates were sampled between March and June 2012 from cattle, pig and broiler farms in Mecklenburg -Western Pomerania (cattle farms, n¼6; pig farms, n¼15; broiler farms, n¼2). Five ESBL-positive E. coli isolates were obtained from farm workers (cattle farms, n¼3; pig farms, n¼2).
All bacterial cultures were grown overnight on Columbia blood agar (Oxoid Deutschland GmbH, Wesel, Germany) in a 368C ambient atmosphere. For DNA extraction, a single bacterial colony was transferred into 100 mL of 5% Chelex w 100 Resin (Bio-Rad Laboratories, Hercules CA, USA), boiled for 10 min at 1008C and centrifuged for 2 min at 12 000 g. Subsequently, 60 mL of the supernatant including the DNA was transferred into a new reaction tube and used as PCR template in a 1 : 100 dilution.
Moreover, we analysed whether the novel assay was able to differentiate reliably between co-occurring ESBL and non-ESBL phenotypic bla TEM and bla SHV alleles within the same isolate. Due to a lack of WT positive controls, we artificially created samples with co-occurring alleles of both phenotypes. The extracted DNA of one positive control sample with known ESBL phenotypic bla SHV or bla TEM was combined with the extracted DNA of another positive control sample with known non-ESBL phenotypic bla SHV or bla TEM (1 : 1 concentration). In this way, three artificial samples were created, two for bla SHV [bla SHV-11 (non-ESBL) plus bla SHV-12 (ESBL); bla SHV-11 plus bla SHV-2 ] and one for bla TEM [bla TEM-1 (non-ESBL) plus bla TEM-52 (ESBL)]. All samples were used in a 1 :100 dilution as templates for the bla SHV and bla TEM PCRs as described below.
PCR amplification and amplicon sequencing
Initially, DNA of all examined isolates (10 reference strains and 101 uncharacterized isolates) was screened with a multiplex PCR described by Fang et al. 10 for the presence of bla SHV , bla TEM and bla CTX-M .
Subsequently, the 101 uncharacterized samples and the 10 positive control strains received from the NRL were subtyped with (i) the novel assay presented in this study and (ii) established subtyping assays for each bla gene/allele group detected in the multiplex screening: 10 bla TEM and bla SHV ;
11 bla CTX-M-1 ; 12 bla CTX-M-2 and -9 13 and bla CTX-M-8/-25 14 (originally designed specifically for bla CTX-M-25 ). Primers (Sigma-Aldrich Chemie, Taufkirchen, Germany) were either derived from established bla subtyping assays 11 -14 or newly designed (Table 1) . Primer design was performed in three steps: first, all available sequences of the respective bla genes were downloaded from NCBI GenBank (http://www.ncbi.nlm.nih.gov/) or from the Lahey b-lactamase database managed by K. Bush and G. A. Jacoby (http://www.lahey.org/studies/; both databases were accessed in July 2013) and aligned using the MEGA software version 4.0. 15 Second, potential primer binding sites were manually identified (Table S2 ) and their ability to amplify the region of interest was experimentally evaluated. Third, the primer combination that generated the largest amplicon was finally chosen for inclusion in the assay. The novel assay includes singleplex PCRs for bla SHV and bla TEM and a multiplex PCR for bla CTX-M , all executed with the same PCR protocol. The primers were used at a concentration of 5 mM and with equal distributions of each primer within the multiplex mixture for bla CTX-M . One 19 mL PCR reaction mixture contained 10 mL of REDTaq ReadyMix (Sigma-Aldrich), 4 mL of a forward and reverse primer mixture of the relevant bla gene/allele group and 5 mL of template DNA in a 1 : 100 dilution. Amplification for all bla genes was carried out in a T1 or TProfessional thermocycler (Biometra GmbH, Gö ttingen, Germany) as follows: lid preheated to 988C, activation step for 3 min at 958C, denaturation for 40 s at 958C, annealing for 45 s at 558C, elongation for 60 s at 728C (the last three steps repeated for 30 cycles in total) and a final elongation for 5 min at 728C. Agarose gel electrophoresis was performed to check for the presence of bla genes and PCR quality. A negative control was used for every primer group to rule out false positive results. Positive PCR products were subsequently purified using the enzymes exonuclease I (New England Biolabs GmbH, Frankfurt-Hoechst, Germany) and shrimp alkaline phosphatase (USB Amersham, Freiburg, Germany), modified from the method of Dugan et al. 16 Briefly, 5 mL of the PCR product was incubated with 1.5 U of each enzyme at 378C for 45 min, followed by 10 min at 808C for enzyme heat inactivation. For sequencing, 2 mL of the purified amplicons was mixed with 0.5 mL of premix from the ABI Prism BigDye Terminator v3.1 Ready Reaction Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) plus 1.8 mL of Tris-HCl-MgCl 2 buffer (400 mM Tris-HCl; 10 mM MgCl 2 ; pH 9) and 2 mL of the sequencing primer (5 mM each corresponding PCR primer) in a total volume of 10 mL. The cycling reaction conditions included 25 cycles of denaturation (10 s at 968C), annealing (5 s at 548C) and extension (4 min at 608C). Finally, the sequencing reaction products were purified using the BigDye X Terminator Kit method as recommended by the manufacturer (Applied Biosystems) and loaded onto a 3130xl Genetic Analyzer (Applied Biosystems) for capillary sequencing.
Sequencing data analysis was performed using Ridom SeqSphere + software version 1.0 (Ridom GmbH, Mü nster, Germany). The consensus nucleotide and amino acid sequences obtained were compared with all currently known bla SHV , bla TEM and bla CTX-M alleles derived from NCBI GenBank according to the Lahey b-lactamase database. For maximum transparency, all indistinguishable resulting alleles were specified.
Results
In order to establish the novel assay, 10 reference strains with known bla genotypes were subtyped as positive controls with the novel assay and established subtyping methods for bla SHV , bla TEM and bla CTX-M . 11 -14 In all cases, the novel as well as the established reference assay resulted in the expected enzymes ( Table 2 ). The primers for bla CTX-M-25 were shown to amplify Novel bla TEM , bla SHV and bla CTX-M subtyping assay 711 JAC bla CTX-M-8-like alleles reliably. Four of the 10 b-lactamases occurring in the reference strains were precisely determined by the novel assay. The remaining enzymes could be classified into groups of two (n¼ 2) or three (n¼ 2) highly similar alleles. In two cases, the novel and the reference assay similarly detected two allelic variants of the same bla gene within one sample [bla TEM-1/-98/-206 (non-ESBL) and bla TEM-52/-92 (ESBL); bla CTX-M-1/-61 and bla CTX-M-32 ]. The novel assay provided a higher discriminatory ability compared with the established assay by Dallenne et al.
11
for bla SHV-12 and bla SHV-2 . The novel and established subtyping assays determined the remaining expected bla alleles equally.
In a second step, 101 uncharacterized clinical and livestockassociated isolates were subtyped with the novel assay and the established subtyping methods for bla SHV , bla TEM and bla CTX-M . For each isolate, the same bla genes and their corresponding allele groups were determined by the novel and the related reference assay (Table 3) . One pig-associated and one clinical E. coli possessed two copies of bla TEM [bla TEM-15 (ESBL) and bla TEM-135 At least one positive control strain was tested for each primer pair, except for group bla CTX-M-25 . However, bla CTX-M-25 is similar to bla CTX-M-8 and may therefore be amplified with the same primers. For each group, the expected enzyme was detected with the novel and the established assay (sometimes undistinguishable from other closely related alleles). The oligonucleotide sequences are displayed in forward (F) and reverse (R) orientation for the detection of different allele groups of the b-lactamase genes bla SHV , bla TEM and bla CTX-M . Primers for bla CTX-M were used in a multiplex PCR; primers for bla SHV and bla TEM were used in singleplex PCRs. All targets were amplified with the same PCR protocol.
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(non-ESBL)], which were similarly identified by the novel and the reference assay. 11 One novel CTX-M-1-like b-lactamase [one SNP to CTX-M-1, position 380 C T (Val Ala)] was similarly determined with the novel and the established assay 12 and submitted to the Lahey database (CTX-M-158; GenBank accession number KM211691). In total, 17 different alleles of the examined bla genes were detected in the present sample set, including the reference strains. Three of these 17 bla alleles were identified with higher discriminatory ability by the novel assay; the remaining 14 were identified with identical discriminatory ability to the respective reference assay. In total, 149 bla alleles were detected in the 111 isolates, of which 49 were identified with higher discriminatory ability by the novel assay.
Co-occurring alleles of one bla gene could successfully be distinguished in all artificially created samples (bla TEM , n ¼1; bla SHV , n¼ 2). If the allelic variants differed in one position, a clear ambiguity was seen in the chromatogram obtained by sequencing (Figure 1) . Moreover, in addition to the intentionally created samples with double allelic variants, this clear differentiation between two alleles of the same bla gene was also observed in two samples from the test set and two reference strains (as described above).
In the following, the epidemiology of detected b-lactamases was evaluated. CTX-M was by far the most prevalent ESBL enzyme observed in livestock-associated as well as in clinical isolates (Table 3) . It was found in 92.2% of all pig-, cattle-and humanassociated isolates, but in none of the broiler-associated E. coli. In contrast, all broiler-associated E. coli possessed the ESBL SHV-12, which occurred only rarely in clinical samples (n¼2) and not at all in the pig-and cattle-associated isolates. TEM was found in about one-third of all samples, with equal distribution among the different host species (38.6%). It was mainly detected as the non-ESBL enzyme TEM-1/-98/-206 (89.5% of all TEMs).
The overall diversity of b-lactamases was much lower in livestock-associated E. coli isolates than in clinical samples: nearly all CTX-M-positive E. coli isolated from pigs and cattle possessed type CTX-M-1/-61 or closely related enzymes; only one CTX-Mpositive cattle-associated E. coli possessed another CTX-M type (CTX-M-2/-20/-97; Table 3 ). Regarding bla TEM , only the non-ESBL phenotypic variant TEM-1/-98/-206 occurred in the pig-and cattle-associated samples, with the exception of one pigassociated E. coli, which possessed TEM-15 (ESBL) and TEM-135 (non-ESBL). No bla SHV was detected in cattle-or pig-associated E. coli. The broiler-associated E. coli all possessed SHV-12 plus TEM-1/-98/-206 (n¼5) or TEM-135 (n¼ 1).
In contrast, the clinical isolates harboured six different CTX-M types. The most prevalent was CTX-M-15/-28/-88 (40% of all samples), followed by CTX-M-1/-61 (27.5%) and CTX-M-14/-17 (12.5%). CTX-M-27, CTX-M-9 and CTX-M-3/-22 were detected in one isolate each. Moreover, three clinical E. coli possessed a bla SHV gene (SHV-12, n ¼ 2; SHV-5/-55, n ¼ 1). As mentioned above, TEM occurred mainly in the form of TEM-1/-98/-206, but was also rarely found as TEM-52/-92, TEM-12, TEM-15 and TEM-135 (n¼ 1 each; Table 3 ).
Four of the five E. coli isolates sampled from asymptomatic farm workers on cattle and pig farms possessed the cattle-and pig-prevalent ESBL CTX-M-1 allele group, two of them additionally had a TEM-1/-98/-206 enzyme. One farm worker-hosted E. coli possessed CTX-M-15/-28/-88. All of these results were confirmed with the previously established subtyping assays.
Whereas 64 of all the characterized isolates harboured only one of the examined bla genes, 37 possessed two different bla Novel bla TEM , bla SHV and bla CTX-M subtyping assay 713 JAC genes. Among the latter, 27 exhibited different combinations of bla CTX-M and bla TEM alleles. The proportion of E. coli with one or two bla genes was equally distributed among host species.
Discussion
Our novel PCR-based bla subtyping assay was successfully used to specify b-lactamase genes in well-described reference/positive control strains as well as in previously unknown ESBL-producing E. coli isolates of clinical and livestock-associated origin. The results obtained with respect to the determined ESBL allele were equal to or better than those obtained by previously established ESBL subtyping assays. In particular, in cases of SHV-12, SHV-2 and TEM-1/-98/-206, the novel assay had a higher discriminatory ability compared with the previously established assay 11 due to a longer PCR amplicon. All other detected alleles were identified with equal discriminatory ability by our assay and the respective established subtyping assay.
The major advantage of the presented assay compared with other methods is its high practicability due to the fact that all three examined bla genes can be amplified with the same PCR protocol. This also results in a short hands-on-time of 10 -15 min/sample (10 -15 E/sample) and completion of the assay, including the bioinformatic analysis, within 2 working days. To our knowledge, this is the only assay that enables researchers to amplify all major ESBL-relevant allele groups of bla SHV , bla TEM and bla CTX-M specifically in a universal PCR approach, resulting in amplicons that are large enough to provide a solid basis for accurate enzyme determination by Sanger sequencing. In addition, the assay enables the researcher to distinguish reliably between ESBL and non-ESBL SHV and TEM b-lactamases if they occur in the same isolate. It is even possible to detect multiple copies of bla CTX-M genes of the same allele group. This was shown in artificially created and WT isolates (Figure 1) .
One limitation of our study was the lack of experimental data for the detection of allele group bla CTX-M-25 due to the unavailability of a suitable reference strain. Nevertheless, in silico analyses showed that our primers ought to be able to amplify the related alleles specifically (Table S2) . Moreover, the CTX-M-25 primers were shown to reliably amplify the closely related allele group CTX-M-8, and thus their general functionality in the assay can be attested.
It should be noted that our novel assay, as well as most established bla subtyping methods, uses primers that bind within the open reading frame of the respective bla gene. Thus, those parts of the gene that do not lie within the amplified region cannot be taken into account for the discrimination of specific bla alleles; therefore, alleles that differ only in this part of their nucleotide sequences remain indistinguishable. Nevertheless, published studies frequently report the identification of one specific enzyme (usually the most common one), even though other allelic variants cannot be excluded. Thus, many results in the literature are, strictly speaking, only an approximation of the 'real' situation. To be aware of this inaccuracy, we believe that known alternative allele(s) should be specified, as we did here (Tables 2 and 3 ). Due to the large portion of sequence information in our assay, we were able to reduce the number of potentially possible alleles (for the ones detected in the sample set) to a maximum of three (Tables 2  and 3 ). They differed by one or two point mutations, which were located within the gene's first or last few bases.
The analysed clinical isolates represented all ESBL-producing E. coli of a certain patient population (ICU patients/bloodstream infections) detected at our university hospital during two study periods of 14 and 12 months, respectively, which enables us to further analyse their epidemiology. We found CTX-M-15/-28/-88, CTX-M-1/-61 and CTX-M-14/-17 to be the most prevalent ESBL types; they were present in 40.0%, 27.5% and 12.5% of all clinical samples, respectively. This is in accordance with previous detections of ESBL-producing E. coli in German hospitals and the community. 17 -19 In contrast to the human isolates, the livestockassociated ESBL E. coli analysed in this study did not reflect their precise epidemiology due to unstructured sampling. Nevertheless, the observed bla allele frequencies in the examined samples basically matched the results obtained by multiple previous studies (summarized and reviewed by Ewers et al. 20 ). In summary, we developed and evaluated a highly discriminatory and efficient molecular assay for the subtyping of clinically important ESBL genes. This assay will help to elucidate the molecular epidemiology of ESBL-producing bacteria and possible Strauß et al.
transmission routes among livestock animals, the environment, people in the community and patients in hospitals.
